Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Friday.

Several other equities analysts have also weighed in on SPPI. Zacks Investment Research lowered shares of Spectrum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Jefferies Group LLC set a $9.00 target price on shares of Spectrum Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 25th. BidaskClub lowered shares of Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. ValuEngine upgraded shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Finally, Guggenheim assumed coverage on shares of Spectrum Pharmaceuticals in a report on Monday, October 23rd. They set a “buy” rating and a $32.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $21.40.

Spectrum Pharmaceuticals (NASDAQ:SPPI) traded up $0.43 during trading hours on Friday, hitting $19.66. 1,470,000 shares of the company traded hands, compared to its average volume of 2,678,268. The company has a current ratio of 3.08, a quick ratio of 2.93 and a debt-to-equity ratio of 0.56. Spectrum Pharmaceuticals has a 1-year low of $3.34 and a 1-year high of $21.95.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.06). The business had revenue of $36.40 million for the quarter, compared to analyst estimates of $33.27 million. Spectrum Pharmaceuticals had a negative net margin of 58.94% and a negative return on equity of 32.72%. The business’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.07) EPS. sell-side analysts forecast that Spectrum Pharmaceuticals will post -1 EPS for the current year.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/04/spectrum-pharmaceuticals-inc-sppi-stock-rating-reaffirmed-by-hc-wainwright.html.

A number of hedge funds have recently modified their holdings of SPPI. State of Alaska Department of Revenue lifted its holdings in Spectrum Pharmaceuticals by 77.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 13,918 shares of the biotechnology company’s stock worth $103,000 after buying an additional 6,058 shares in the last quarter. Piedmont Investment Advisors LLC acquired a new position in Spectrum Pharmaceuticals in the 2nd quarter worth $114,000. Municipal Employees Retirement System of Michigan lifted its holdings in Spectrum Pharmaceuticals by 5.6% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 16,720 shares of the biotechnology company’s stock worth $125,000 after buying an additional 880 shares in the last quarter. Pillar Pacific Capital Management LLC acquired a new position in Spectrum Pharmaceuticals in the 2nd quarter worth $138,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in Spectrum Pharmaceuticals by 87.5% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 21,347 shares of the biotechnology company’s stock worth $159,000 after buying an additional 9,960 shares in the last quarter. Hedge funds and other institutional investors own 66.41% of the company’s stock.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.